Key result
Surgical resection of cardiac myxoma resulted in no hospital deaths and no tumor recurrence during a mean follow-up of 105.7 months.
Cohort (n=74)
No
Surgical resection of cardiac myxoma is a safe and curative treatment, with no tumor recurrence observed after complete resection during long-term follow-up.
Answers are grounded in this paper and cite their sources.
Affirms low risk with resection in this series; leaves open generalizability beyond small case reports.
Although cardiac myxoma is rare, it is the most common primary cardiac tumor. Seventy-four cases of cardiac myxoma that were surgically treated in our center between August 1980 and February 2005 were retrospectively reviewed. The mean patient age was 50.4 +/- 15.0 (range 7-80) years, and 53 patients (71.6%) were female. The most common preoperative symptom, occurring in 44 patients, was dyspnea. The interval from onset of symptoms to surgery was 9 months. Seventy cases were located in the left atrium, 3 in the right atrium and 1 in the right ventricle. The myxoma in the right ventricle could not be resected completely, due to severe infiltration. Cardiopulmonary bypass and aortic cross clamp times were 100.4 +/- 37.1 and 64.8 +/- 29.8 minutes, respectively. There were no hospital deaths, and 7 patients suffered from postoperative complications including atrial fibrillation in 2 cases. During the follow up period (mean 105.7 +/- 73.6 months), there was no tumor recurrence and 6 late deaths that were not related to the underlying tumor. There was no evidence of tumor growth in the cases with incomplete resection during the 14-month follow-up. In conclusion, in this study there was no recurrence of tumors after complete resection and surgical resection is considered to be the curative method of treatment for cardiac myxoma.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2006) conducted a cohort in Cardiac myxoma (n=74). Surgical resection was evaluated on Tumor recurrence and hospital mortality. Surgical resection of cardiac myxoma resulted in no hospital deaths and no tumor recurrence during a mean follow-up of 105.7 months.
Synapse has enriched 10 related papers. Consider them for comparative context: